View allAll Photos Tagged stemcell
Adam Heathfield, Director Science Policy Europe, Pfizer
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Erik Tambuyzer, Managing Director, Center for Biomedical Innovation (CMI)
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Sometimes it takes a mother’s touch to soothe the scrapes and pains of growing up. But not even a mother’s love can completely erase the anguish of childhood diabetes.
Kim Hurshman and her two sons in Springfield, Missouri, know this as well as anyone does – Type 1 diabetes has been an unwelcome participant in both boys’ lives. Little did they know upon the first diagnosis the traumatic treatments that would follow.
Judging by the tears Mrs. Hurshman has shed for her children, the pain isn’t theirs alone.
Fortunately, scientists are working toward a cure. Visit www.MissouriCures.com to learn about the most recent advances – and how you can help protect medical research in Missouri.
Mr. Joseph Vicente, Chief Operating Officer of Cord Blood America, Inc., giving his speech at the Grand Opening of the company's new corporate office and lab in Las Vegas, Nevada on January 22, 2010.
Stem cell patch allows word-blind patients to read again: bit.ly/2u50Dkc #stemcells #science #tuesdaymotivation #tuesnews
Thomas Dentzer, Luxembourg BioHealth Cluster Manager, Luxinnovation
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
For more information about the Ethics in a Science Classroom Workshop, please visit www.nwabr.org/teachers/ethics-science-classroom
Are you living in League City Texas and your dog is suffering from IMHA and ITP? Are you looking for a good animal hospital for his treatment? StemCell Safari League City is one of the best hospitals in Texas for the treatment of immune-mediated hemolytic anemia (IMHA).
Symptoms include lethargy, weakness, panting, rapid breathing, poor appetite, vomiting, reluctance to exercise, spontaneous bruising, dark urine, yellow in the white of the eyes, and yellow or pale gums.
If you want to get more information about IMHA and ITP then you can visit our Stemcell Safari Regenerative Therapy website and call us at 281-332-5612.
Senator Chris Dodd and Congressman Chris Murphy (CT-5) joined stem cell researchers, doctors, patient advocates, and Connecticut residents suffering from diseases that may be helped through stem cell research to celebrate President Obama’s recent Executive Order overturning the restrictive stem cell policies put in place by President Bush. Dodd and Murphy were also joined by Cindy Tian, the widow of Dr. Xiangzhong “Jerry” Yang, head of the University of Connecticut’s Center for Regenerative Biology and leading stem cell researcher who passed away last month.
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Jan Schrooten, Research Manager: Biomaterials & Tissue Engineering, KU Leuven
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
Adam Heathfield, Director Science Policy Europe, Pfizer
Magda Chlebus, Director Science Policy, EFPIA
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
"The cover image illustrates a switch during mouse stem cell differentiation in the composition of the PRC1 Polycomb complex. Cbx7 proteins are replaced by Cbx2 and Cbx4, reflecting their specific roles in pluripotency and differentiation, respectively, as reported by Morey et al. (47–62) and O'Loghlen et al. (33–46) in this issue. Cover design by Iris Joval, Lluis Morey, and Luciano Di Croce."
Reference: Morey et al., Nonoverlapping Functions of the Polycomb Group Cbx Family of Proteins in Embryonic Stem Cells, Cell Stem Cell (2012), doi:10.1016/j.stem.2011.12.006
More info on the group at: www.crg.es/luciano_di_croce
Vincent Clay, Manager, EU Government Affairs & Stakeholder Engagement, EU Representation Office, Pfizer
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen
The University of Louisville Division of Cardiovascular Medicine presented the 21st Annual Leonard Leight Lecture on December 10, 2014 in Kornhauser Auditorium on the UofL Health Sciences campus.
The special guest speaker for 2014 was Victor J. Dzau, M.D., President of the Institute of Medicine.
Dr. Dzau presented "Molecular Approaches to Cardiac Regeneration" focusing on understanding cell-based therapy for cardiac regeneration.
Mr. and Mrs. Broad named this with their $25 million gift. The people of California paid for it with a $3 billion bond measure. All to a good cause in one of the best medical centers in the world.
bit.ly/2wY0Q59 ... STUDY SHOWS ADIPOSE STEM CELLS MAY BE THE CELL OF CHOICE FOR THERAPEUTIC APPLICATIONS ... Researchers at the University of Guelph, University of Western Ontario and Aarhus University, Denmark, ran a battery of tests comparing the physiology characteristics of stem cells derived from adipose tissue versus bone marrow. ... #iffieokoronkwo #stemcells #terhapy #therapeutic
The patient receives high-dose chemotherapy and/or radiation therapy, followed by the stem cell transplant. A donor's stem cells are then transfused into the patient's blood. The transplanted stem cells go from the patient's blood to his or her marrow. For more info: regenorthosport.in/stemcell-therapy-india-regenexx/
Event : Headshot & Product
Date : 29th March 2015 (13:30 - 18:00)
Location : U Delight @ OnNut Station
Model : Lookkate
Product : Fixx Stemcell Serum
FB : Fixx Stemcell Serum
IG : Fixx Stemcell Serum
Call : 086 0397 8847
Gallery : www.flickr.com/photos/photo_network_group/sets/
Join with Photo Network Group :-
The University of Louisville Division of Cardiovascular Medicine presented the 21st Annual Leonard Leight Lecture on December 10, 2014 in Kornhauser Auditorium on the UofL Health Sciences campus.
The special guest speaker for 2014 was Victor J. Dzau, M.D., President of the Institute of Medicine.
Dr. Dzau presented "Molecular Approaches to Cardiac Regeneration" focusing on understanding cell-based therapy for cardiac regeneration.
Senator Chris Dodd and Congressman Chris Murphy (CT-5) joined stem cell researchers, doctors, patient advocates, and Connecticut residents suffering from diseases that may be helped through stem cell research to celebrate President Obama’s recent Executive Order overturning the restrictive stem cell policies put in place by President Bush. Dodd and Murphy were also joined by Cindy Tian, the widow of Dr. Xiangzhong “Jerry” Yang, head of the University of Connecticut’s Center for Regenerative Biology and leading stem cell researcher who passed away last month.
Magda Chlebus, Director Science Policy, EFPIA
Jonathan Brenton, British Ambassador to Belgium
Duane Schulthess, Commercial Director, Science|Business
What is the state of R&D, funding, and infrastructure in Europe? This Science|Business Policy Roundtable took place at the UK Representation to the EU in Brussels on 18 October 2012.
Regenerative Medicine is one of the most exciting and promising fields of biomedical research today. Europe currently leads the world in therapeutic applications and medicines in this technology, and has successfully seen the first companies working in the field to spin-out from research universities with EMA approved products currently in the market.
However, with the recent patent ruling by the European Court of Justice and the debate regarding continued funding in Horizon 2020, what challenges exist for Europe to maintain its research lead in this field?
Science|Business hosted a roundtable discussion of thought leaders and policy to make recommendations as to what the EU should do to improve the infrastructure and research climate for new stem cell technologies and regenerative medicines in Europe.
Pictures by Carlos Nomen